Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Methylnaltrexone Bromide||Relistor||MNTX||VEGFR Inhibitor (Pan) 32||Relistor (methylnaltrexone bromide) is a mu-type opioid receptor inhibitor and is approved for constipation, but it has also been shown to inhibit VEGFRs and angiogenesis (PMID: 16820176).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01015222||Phase I||Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab||Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies||Active, not recruiting|
|NCT04083651||Phase II||Methylnaltrexone Bromide||A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer||Recruiting|